RAPP NASDAQ
Rapport Therapeutics, Inc. Common Stock
1W: -3.3%
1M: -0.2%
3M: +23.3%
YTD: +30.6%
1Y: +259.1%
$37.72
+1.02 (+2.78%)
Weekly Expected Move ±7.8%
$31
$34
$37
$40
$43
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (29)
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics GAAP EPS of -$0.42, revenue of $0.02M
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP
Rapport Therapeutics GAAP EPS of -$0.72 misses by $0.03
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rapport Therapeutics与Tenacia Biotechnology宣布达成大中华区RAP-219开发与商业化战略合作
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Brokerages Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $47.00
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) PT at $48.33
David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock
Fantôme Rapport Launches in English — A Romance, Horror, and Mystery Adventure Aboard a Ghostly Luxury Liner
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 6,567 Shares
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting